This trial is active, not recruiting.

Condition anemia, sickle cell
Treatment far infrared radiation (5μm to 20μm wavelength)
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date January 2008
End date September 2008
Trial size 10 participants
Trial identifier NCT00599482, GAAD-SCC-CTP1


Most patients with sickle-cell disease have periodic intensely painful episodes. To manage this pain, we are proposing the drinking of at least 500 mL of water followed by far infrared radiation.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose supportive care
Far Infrared Radiation
far infrared radiation (5μm to 20μm wavelength)
Far infrared radiation for 30 to 40 minutes during each session.

Primary Outcomes

Pain Management
time frame: 40 minutes

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - People with sickle cell disease Exclusion Criteria: - None

Additional Information

Official title Phase 1 Study to Examine the Use of Far Infrared Radiation for Pain Management During Sickle Cell Crisis
Description Painful sickle cell crises are treated with hydration and analgesics. Ischemia is an absolute or relative shortage of the blood supply to an organ. Relative shortage means the mismatch of blood supply (oxygen delivery) and blood request for adequate oxygenation of tissue. It is hereby postulated that far infrared radiation of the body will promote blood and oxygen supply to the affected tissues. In addition, the analgesic properties of far infrared will alleviate pain due to the crisis.
Trial information was received from ClinicalTrials.gov and was last updated in January 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..